A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.
…
continue reading
Phase3 Podcasts
A podcast to share the tools, tips, tricks and routines of the best biotech executives in the industry in order to help develop the next generation of biotech leaders and expedite the launch of new therapies and transform the lives of patients' all over the world.
…
continue reading
1
VAXXED: And the winner is... with OneVentures and Ose Immunotherapeutics
27:32
27:32
Play later
Play later
Lists
Like
Liked
27:32
Moderna and BioNTech are getting all of the attention with their phase 3 clinical trials for lung cancer and melanoma. But someone else is already further ahead. French company Ose Immunotherapeutics has already done a phase 3 study for non small cell lung cancer, and if the final run of work confirms that data it will have the first cancer vaccine…
…
continue reading
Cancer vaccines are an area that anyone who is anyone is getting into, but it's a field led largely by academics, not-for–profits, and specialist researchers. So this week we go back to basics - science that is. Australia may not have many cancer vaccine biotechs but – as we pointed out in episode one with the godfather of cancer vaccines, professo…
…
continue reading
1
VAXXED: Boom or bust? With Chris Kallos and Pitt Street Research
18:30
18:30
Play later
Play later
Lists
Like
Liked
18:30
In some ways, cancer vaccines are a history of hype and hope, over success. But that hasn't stopped people from trying. In 2024, biotech CEOs are hoping that this time, it's different. Research houses are predicting significant market growth come 2030, mRNA vaccines are making it through to phase three clinical trials for the first time, and there …
…
continue reading
1
Building Effective Teams and Career Success ft. Bob Ferrigno
51:35
51:35
Play later
Play later
Lists
Like
Liked
51:35
In this episode of The Phase 3 Biotech Leadership Podcast, we are joined by Bob Ferrigno, Sr. Vice President of Global Sales and Marketing at SynergEyes, who shared insights from his extensive career in the biotech industry, focusing on leadership, team-building, and career development. Bob discusses his assertive career management at Becton Dickin…
…
continue reading
1
VAXXED: Deadly infection, with Imugene and ImmVirX
23:13
23:13
Play later
Play later
Lists
Like
Liked
23:13
Cancer vaccines are a very niche section of cancer treatments. But two companies in Australia – the only two so far to go public with their work in this arena –are working on an even niche area within this. And one says their work is not a vaccine. The other does. So what gives? Well it depends on what you want to focus on: the deadly infectious na…
…
continue reading
1
VAXXED: From Gardasil to mRNA, with Dr Ian Frazer and Wilsons Advisory
28:39
28:39
Play later
Play later
Lists
Like
Liked
28:39
Cancer vaccines started out as prevention. Think Gardasil for cervical and oral cancers caused by HPV, and the hepatitis B vaccine for liver cancer. But today the science has moved on, to therapy vaccines. Vaccines that take immune cells and "rub their little noses in the antigen" - the substance that forces the body to sit up and take notice of a …
…
continue reading
1
The Importance of Mastering Change as a Biotech Leader ft. Dan Couto
55:01
55:01
Play later
Play later
Lists
Like
Liked
55:01
In this episode of the Phase 3 Biotech Leadership Podcast, we sit down with Dan Couto, Chief Operating Officer of Vedanta Biosciences, to explore the critical role of mastering change in biotech leadership. Dan shares his diverse experiences across the biotech sector, highlighting key leadership skills such as problem-solving, effective communicati…
…
continue reading
1
NUKED: Our nuclear future, with Novartis, Wilsons Advisory and Cyclotek
34:16
34:16
Play later
Play later
Lists
Like
Liked
34:16
Drone-deliveries of radioactive medicines and diagnostics to Australia's far-flung towns. Radiopharmaceuticals matched with genetic information to tailor precisely the right dose and isotope to a person's cancer. Pan-cancer drugs that fix many tumours, not just one. Miniature particle accelerators. These are the hopes, dreams and expectations we ca…
…
continue reading
The rule of thumb in biotech is that it costs around $1 billion to bring a new therapy from lab to market. Protecting that investment is the patent system. But what if part of your product is not made by your contract manufacturer, but by the people who are giving it to patients? Ie, their doctors. We explore an example in Australia where this push…
…
continue reading
1
NUKED: Australia the nuclear power, with entX and Cyclowest
29:58
29:58
Play later
Play later
Lists
Like
Liked
29:58
Can Australia create a mine to lab to bedside production line for radiopharmaceutical medicine? It has the reactor, biotechs and the hospitals to do that last two, and even has a growing pool of expertise to run these. What it doesn't have, yet, is many advanced manufacturers to do the first bits, the critical parts such as sifting through old mine…
…
continue reading
1
How to Transcend Your Function and Become a Holistic Biotech Business Leader - ft. Shawnte Mitchell
47:20
47:20
Play later
Play later
Lists
Like
Liked
47:20
In this episode of The Phase 3 Biotech Leadership Podcast, we welcome Shawnte Mitchell, Chief Legal Officer, C-Suite Executive and Business Leader. Listen to the full episode to hear: Shawnte share her unique career journey, highlighting major pivots from biological sciences to healthcare law and eventually into corporate leadership roles. Alex and…
…
continue reading
1
NUKED: The IP game, with Clarity Pharmaceuticals and Radiopharm Theranostics
26:25
26:25
Play later
Play later
Lists
Like
Liked
26:25
The question we are dancing around in episode 3 of NUKED is whether locking down isotopes supply chains are really the only way to play the radiopharmaceutical game. We ask Clarity Pharmaceutical executive chair Alan Taylor and Radiopharm Theranostics executive chair Paul Hopper how their companies are instead owning the IP, or banking a portfolio …
…
continue reading
1
NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals
29:47
29:47
Play later
Play later
Lists
Like
Liked
29:47
In early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem. Novartis' prostate cancer therapy Pluvicto, released only the year before, was suddenly in short supply, snarling up just in time treatment schedules. In 2024 the supply chain problem is with the isotope Actinium 225, which *everyone* wants for clinical tri…
…
continue reading
1
NUKED: Why radiopharmaceuticals are exploding, with Peter MacCallum Cancer Centre and HB Biotechnology
25:34
25:34
Play later
Play later
Lists
Like
Liked
25:34
The radiopharmaceuticals sector is on a knife point. The scope of what nuclear medicine can do is exploding. But the radioisotopes that biotechs need to make those therapies are in very, very short supply. Major clinical trials are hitting pause because of shortages of critical nuclear isotopes, and the world's biggest pharmaceutical companies are …
…
continue reading
1
The Silent Killer: The sci-fi episode, with Certa Therapeutics and University of Sydney CTC
27:59
27:59
Play later
Play later
Lists
Like
Liked
27:59
Wearable kidneys. Organs on a chip. Xenotransplantation. The future is here. But is that the future people in biotech are truly looking to? Because the future that Certa Therapeutics CEO Darren Kelly is looking to is much less 1980s sci-fi and more... Apple watch. And in a future where the numbers point to a rise in lifestyle diseases thanks to die…
…
continue reading
1
The Silent Killer: Prevention is the next cure, with Kidney Health Australia and Proteomics International
23:06
23:06
Play later
Play later
Lists
Like
Liked
23:06
We may have led you on a bit in the first two episodes... kidney disease is still a big problem despite the massive shifts forward in treating it. There is a long way to go to bring medical sectors -- and governments -- along as well. This episode features Breonny Robson, general manager of clinical and research at Kidney Health Australia and Richa…
…
continue reading
1
The Silent Killer: Who has the killer apps? With Dimerix and PYC Therapeutics
24:40
24:40
Play later
Play later
Lists
Like
Liked
24:40
We speak to Dimerix CEO Dr Nina Webster about why investors are thrilled with her company, as it nears the midway point for its Phase III clinical trial for the rare disease focal segmental glomerulosclerosis (FSGS). And we talk to PYC Therapeutics CEO Dr Rohan Hockings about how his company's tech actually works to treat polycystic kidney disease.…
…
continue reading
1
The Silent Killer: Why biotechs are all in on kidney disease, with University of Sydney CTC and Chris Kallos
26:55
26:55
Play later
Play later
Lists
Like
Liked
26:55
Kidney disease is a silent killer, with only 10% of all people knowing they have it before damage has been done. But in the last five years there's been a surge of work that's resulted in the FDA approving some blockbuster drugs in the last 18 months. Billion-dollar takeovers are now on the table and the tiny number of Australian biotechs in this s…
…
continue reading
Life sciences more than anywhere else is the successful mashup of money and tech. I'm Rachel Williamson and this is Phase III, a weekly podcast diving deep into Australian life sciences. In each of our short series, we investigate, interrogate, and explore the most exciting companies and ideas in health science and the investment case for what they…
…
continue reading
1
Best Practice for Late Stage Funding - Kameel Farag, Hari Pujar, Randy Berholtz
50:16
50:16
Play later
Play later
Lists
Like
Liked
50:16
Our expert panel of C-level executives and board members reveal their tips tricks for successful late stage funding rounds. Great insight from: Hari Pujar - Operating Partner at Flagship Therapeutics and COO at Tessera Therapeutics Randy Berholtz - Chair and Chief Executive Officer Chair and Chief Executive Officer - Rancho Santa Fe Bio, Inc. Kamee…
…
continue reading
1
Best Practice for Early Stage VC Funding. Brian McVeigh, Doug Carlson, Mike Tusche
1:00:44
1:00:44
Play later
Play later
Lists
Like
Liked
1:00:44
Our expert panel of hugley successful biotech C-leaders jump into best practices to ensure successful early fund raises in the biotech space. Having raised 100's of millions of dollars between them this is a great listen for all of those joining the fundraising roadshow. Doug Carlson - Cheif Operating and Financial Officer - Avenge Bio Mike Tusche …
…
continue reading
1
Best Practice: Building High Performing CMC teams - Mike Kamarck, Al Boyle, JD Mowery
59:55
59:55
Play later
Play later
Lists
Like
Liked
59:55
Our expert panel of exceptional leaders break down the top 5 traits that all high performing CMC teams have and those areas that are critical to focus on to ensure best results. Panel members: Mike Kamarck - Chairman of Sanofi, Biologics Board Al Boyle - CTO of Alnylam JD Mowery - COO, Treadwell Therapeutics Hosted by Jared Green and Alex Cooke fro…
…
continue reading
1
The challenges of exponential growth on culture - Kristin "KG" Gustafson, Former SVP HR Kite Pharma
54:01
54:01
Play later
Play later
Lists
Like
Liked
54:01
In this interview, KG and I discuss the cultural and leadership challenges that biotech companies face as they go through exponential growth. Drawing upon her experiences at Intercept Pharmaceuticals, Kite Pharmaceuticals and Turnstone Biologics she shares great insight into HOW companies can better serve and prepare themselves for growth.…
…
continue reading
1
The journey from HR to GM / Site Head - Carson Sublet
1:13:42
1:13:42
Play later
Play later
Lists
Like
Liked
1:13:42
A wide ranging interview with Carson Sublett who provides his perspective on what it takes to make it as a successful leader in the Biotech industry today. We cover how he was able to transition from HR to Site Head by creating and empowering his teams.By Alex Cooke - Phase 3
…
continue reading
